Tigatuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tigatuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target TNFRSF10B (TRAIL-R2)
Clinical data
Legal status
?
Identifiers
CAS number 918127-53-4 N
ATC code None
Chemical data
Formula C6406H9924N1716O2012S46 
Mol. mass 144.6 kDa
 N (what is this?)  (verify)

Tigatuzumab (CS-1008) is a monoclonal antibody[1] for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed,[2] Phase II trials for colorectal cancer[3] and non-small cell lung cancer[4] are running, and a study for ovarian cancer has been approved.[5]

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.[6]

A recent study reports on the preclinical validation of 111In-labeled anti-DR5 humanised antibody CS-1008 as a diagnostic tool to study the DR5 occupancy in cancer patients, and establish dose ranges for receptor saturation kinetics in vivo.[7]

References[edit]

  1. ^ WHO Drug Information
  2. ^ NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
  3. ^ NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
  4. ^ NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
  5. ^ NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
  6. ^ NCI: CS-1008
  7. ^ http://clincancerres.aacrjournals.org/content/early/2013/09/17/1078-0432.CCR-12-3104.abstract